$MDVN price target raised to $134 from $119 at William Blair
MDVN target raised to $122 from $113 at Jefferies Jefferies raised its price target for Medivation after Xtandi won FDA approval three months earlier than expected. The firm found the drug's label in-line with expectations and reiterates a Buy rating on the stock.
fridays , never a good time to short momo biotechs when FDA usually does their releases